within Pharmacolibrary.Drugs.ATC.A;

model A03FA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.15,
    Cl             = 0.5116666666666666,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.461,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008666666666666666,
    Tlag           = 660
  );

  annotation(Documentation(
    info ="<html><body><p>Domperidone is a peripherally selective dopamine D2 receptor antagonist used as a prokinetic and antiemetic agent. It is primarily indicated for the treatment of nausea and vomiting, gastroparesis, and symptoms associated with chronic dyspepsia. Domperidone is not approved in the United States, but is available in several other countries, often with restrictions due to concerns about cardiac side effects.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after a single oral dose.</p><h4>References</h4><ol><li><p>Ye, L, et al., &amp; Yang, S (2022). Pharmacokinetics and Bioequivalence of 2 Oral Formulations of Domperidone After Single-Dose Administration in Healthy Chinese Subjects. <i>Clinical pharmacology in drug development</i> 11(9) 1084–1091. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1097&quot;>10.1002/cpdd.1097</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35396924/&quot;>https://pubmed.ncbi.nlm.nih.gov/35396924</a></p></li><li><p>Heykants, J, et al., &amp; Reyntjens, H (1981). On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. <i>European journal of drug metabolism and pharmacokinetics</i> 6(1) 61–70. DOI:<a href=&quot;https://doi.org/10.1007/BF03189516&quot;>10.1007/BF03189516</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7250152/&quot;>https://pubmed.ncbi.nlm.nih.gov/7250152</a></p></li><li><p>Athukuri, BL, &amp; Neerati, P (2017). Enhanced Oral Bioavailability of Domperidone with Piperine in Male Wistar Rats: Involvement of CYP3A1 and P-gp Inhibition. <i>Journal of pharmacy &amp; pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</i> 20 28–37. DOI:<a href=&quot;https://doi.org/10.18433/J3MK72&quot;>10.18433/J3MK72</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28459658/&quot;>https://pubmed.ncbi.nlm.nih.gov/28459658</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A03FA03;
